Breaking News Instant updates and real-time market news.

MDT

Medtronic

$82.24

0.38 (0.46%)

11:24
02/15/18
02/15
11:24
02/15/18
11:24

Medtronic presents data showing 'positive' results from MiniMed system

Medtronic announced that new data from its at-home pediatric study of the MiniMed 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes 11th International Conference in Vienna, Austria. Study results mirror data from the pivotal trial of the system in adults and adolescents, showing patients spent more Time in Range, experienced less glycemic variability, less exposure to hypoglycemia and hyperglycemia, and reduced A1C compared to baseline data using sensor-augmented pumps. The MiniMed 670G system is currently FDA approved in the U.S. for people with type 1 diabetes 14 years of age and older. Data from this study was included in an FDA application in late January to seek future expansion of the current indication to include children 7-13 years of age. Medtronic is also evaluating the system in children 2-6 years of age and will present data from this trial at a future date. However, product labeling currently warns that the system may not be safe for children under age 7 or patients using less than 8 units of insulin per day.

  • 14

    Mar

  • 23

    Mar

MDT Medtronic
$82.24

0.38 (0.46%)

02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
02/12/18
OPCO
02/12/18
NO CHANGE
Target $67
OPCO
Outperform
Dexcom price target lowered to $67 from $72 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom (DXCM) to $67 from $72 on lowered estimates, while reiterating an Outperform rating on the stock. The analyst recently surveyed high-volume U.S. endocrinologists on the latest in continuous glucose monitoring now with Abbott's (ABT) Libre Flash on the market. According to respondents, there is some impact on Dexcom new prescriptions since Libre launch and some current Dexcom patients are interested in switching, but the impact looks within expectations, he contends. Overall, Lichtman believes the rollouts of Libre and Medtronic's (MDT) 670G remain overhangs on Dexcom near-term, but his survey suggests an environment no worse than guidance and conditions on the ground should change again in 2H18 with approval of Dexcom's next-generation G6.
01/18/18
PIPR
01/18/18
NO CHANGE
Target $82
PIPR
Overweight
Insulet is a favored diabetes play on business momentum, says Piper Jaffray
Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.
01/04/18
01/04/18
DOWNGRADE

Underperform
Dexcom to Underperform at Northland
As previously reported, Northland analyst Suraj Kalia downgraded Dexcom (DXCM) to Underperform from Market Perform after Abbott (ABT) announced Medicare coverage for its Libre FGM. The analyst believes it undercuts Dexcom's competitive advantages, and contends that there is additional headline risk vis-a-vis Medtronic' (MDT) Guardian Connect CGM approval in the pipeline. Further, Kalia believes Dexcom's stock is bound to be under pressure over the next 12-18 months.

TODAY'S FREE FLY STORIES

WY

Weyerhaeuser

$26.27

-0.07 (-0.27%)

05:55
04/26/19
04/26
05:55
04/26/19
05:55
Earnings
Weyerhaeuser reports Q1 EPS ex-items 11c, consensus 9c »

Reports Q revenue $1.64B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 17

    May

  • 04

    Jun

GKOS

Glaukos

$71.40

0.31 (0.44%)

05:46
04/26/19
04/26
05:46
04/26/19
05:46
Hot Stocks
Glaukos enters collaboration, distribution agreement with Santen »

Santen Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 05

    Jun

  • 13

    Nov

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

, BIIB

Biogen

$229.78

5.46 (2.43%)

05:43
04/26/19
04/26
05:43
04/26/19
05:43
Hot Stocks
Nightstar: ISS, Glass Lewis recommend holders vote 'FOR' deal with Biogen »

Nightstar Therapeutics…

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

BIIB

Biogen

$229.78

5.46 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 04

    May

  • 29

    May

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:41
04/26/19
04/26
05:41
04/26/19
05:41
Earnings
Sanofi backs FY19 business EPS growth of 3%-5% at CER »

Sanofi continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:39
04/26/19
04/26
05:39
04/26/19
05:39
Earnings
Sanofi reports Q1 business EPS EUR 1.42 vs. EUR 1.28 »

Reports Q1 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:36
04/26/19
04/26
05:36
04/26/19
05:36
Earnings
AstraZeneca backs FY19 core EPS view of $3.50-$3.70 »

Backs FY19 product sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:32
04/26/19
04/26
05:32
04/26/19
05:32
Earnings
AstraZeneca reports Q1 reported EPS 47c, consensus 42c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

05:29
04/26/19
04/26
05:29
04/26/19
05:29
Recommendations
Pros Holdings analyst commentary  »

Pros Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ILMN

Illumina

$318.91

4.47 (1.42%)

05:27
04/26/19
04/26
05:27
04/26/19
05:27
Recommendations
Illumina analyst commentary at Piper Jaffray »

Illumina earnings selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

ALGT

Allegiant Travel

$139.70

6.33 (4.75%)

05:22
04/26/19
04/26
05:22
04/26/19
05:22
Recommendations
Allegiant Travel analyst commentary at Imperial Capital »

Allegiant Travel price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

NFLX

Netflix

$368.20

-5.99 (-1.60%)

05:19
04/26/19
04/26
05:19
04/26/19
05:19
Recommendations
Netflix analyst commentary at Imperial Capital »

Imperial trims Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

05:16
04/26/19
04/26
05:16
04/26/19
05:16
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

05:11
04/26/19
04/26
05:11
04/26/19
05:11
Downgrade
Starbucks rating change at Wells Fargo »

Starbucks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Hot Stocks
Roche, Spark Therapeutics withdraw, refile premerger notification »

Roche (RHHBY) and Spark…

RHHBY

Roche

$0.00

(0.00%)

ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    May

  • 04

    May

  • 28

    May

  • 31

    May

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

VCRA

Vocera

$31.31

0.36 (1.16%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Recommendations
Vocera analyst commentary at Piper Jaffray »

Vocera positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 05

    Jun

ESPR

Esperion

$43.02

1.14 (2.72%)

05:06
04/26/19
04/26
05:06
04/26/19
05:06
Upgrade
Esperion rating change  »

Esperion upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

MDCO

The Medicines Co.

$29.84

0.37 (1.26%)

05:05
04/26/19
04/26
05:05
04/26/19
05:05
Upgrade
The Medicines Co. rating change  »

The Medicines Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 08

    May

RS

Reliance Steel

$91.29

2.46 (2.77%)

05:03
04/26/19
04/26
05:03
04/26/19
05:03
Downgrade
Reliance Steel rating change  »

Reliance Steel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TAL

TAL Education

05:02
04/26/19
04/26
05:02
04/26/19
05:02
Downgrade
TAL Education rating change  »

TAL Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASAZY

Assa Abloy

$0.00

(0.00%)

05:01
04/26/19
04/26
05:01
04/26/19
05:01
Downgrade
Assa Abloy rating change at Jefferies »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BKU

BankUnited

$36.10

-0.39 (-1.07%)

05:00
04/26/19
04/26
05:00
04/26/19
05:00
Downgrade
BankUnited rating change  »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TIGO

Millicom

$57.40

-1.25 (-2.13%)

04:59
04/26/19
04/26
04:59
04/26/19
04:59
Upgrade
Millicom rating change  »

Millicom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$151.26

-5.52 (-3.52%)

04:56
04/26/19
04/26
04:56
04/26/19
04:56
Upgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AXTA

Axalta Coating

$26.71

0.21 (0.79%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Downgrade
Axalta Coating rating change  »

Axalta Coating downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

KRP

Kimbell Royalty Partners

$18.00

0.02 (0.11%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Kimbell Royalty Partners management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.